Systemic factors associated with poor anatomical response to anti-VEGF therapy in patients with diabetic macular edema: evidence from a large clinical cohort - Report - MDSpire

Systemic Influences Linked to Suboptimal Anatomical Outcomes Following Anti-VEGF Treatment in Diabetic Macular Edema Patients: Insights from a Large Clinical Cohort

  • By

  • Xinru Jia

  • Yan Shi

  • Mengxiang He

  • Dongwei Yao

  • Chengfei Lin

  • July 21, 2026

Share

Systemic Influences Linked to Suboptimal Anatomical Outcomes Following Anti-VEGF Treatment in Diabetic Macular Edema Patients

Overview

This study investigates systemic factors affecting anatomical responses to anti-VEGF therapy in diabetic macular edema (DME) patients. Key findings indicate that metabolic status, particularly HbA1c and fasting glucose levels, correlate with treatment outcomes.

Background

Diabetic macular edema (DME) is a major cause of vision impairment among working-age individuals globally. Despite the effectiveness of anti-VEGF therapy as a first-line treatment, many patients do not achieve optimal anatomical responses, highlighting the need to understand systemic influences on treatment efficacy.

Data Highlights

MeasureBaseline3-Month Follow-UpP-Value
Central Macular Thickness (CMT)325.00 μm (IQR: 281.00–448.00 μm)291.00 μm (IQR: 268.00–334.00 μm)< 0.001
Best-Corrected Visual Acuity (BCVA)0.30 (IQR: 0.15–0.50)0.40 (IQR: 0.25–0.50)< 0.001

Key Findings

  • Median CMT decreased from 325.00 μm to 291.00 μm after three months of treatment.
  • Median BCVA improved from 0.30 to 0.40 during the same period.
  • 41.48% of eyes were classified as responders based on a >10% reduction in CMT.
  • Baseline CMT, BCVA, LDL-C, fasting blood glucose, and HbA1c were independently associated with CMT reduction.
  • Higher baseline BCVA and elevated fasting blood glucose were linked to poor anatomical response.

Clinical Implications

The findings indicate that systemic metabolic factors, such as HbA1c and fasting glucose levels, are associated with treatment outcomes in DME patients undergoing anti-VEGF therapy.

Conclusion

Systemic metabolic status significantly influences the anatomical response to anti-VEGF treatment in DME patients.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Michael Javaheri, MD, Retinal Physician, 2015 -- The Importance of Quickly Identifying a Suboptimal Response
  3. Retinal Physician, 2016 -- Managing DME
  4. American Diabetes Association, Diabetes Care, 2026 -- Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes
  5. PubMed -- Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE
  6. PMC -- Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes with Diabetic Macular Edema in Protocol T
  7. Retinal Physician — RPS: From the Podium to the Practice
  8. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
  9. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE - PubMed
  10. Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes with Diabetic Macular Edema in Protocol T - PMC

Original Source(s)

Systemic factors associated with poor anatomical response to anti-VEGF therapy in patients with diabetic macular edema: evidence from a large clinical cohort

  • by Xinru Jia, Yan Shi, Mengxiang He, Dongwei Yao, Chengfei Lin

  • July 21, 2026

Related Content

Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

Retinal Age as Disease Biomarker

Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

  • May 27, 2026

  • 3 min
New Target for Uveitis Therapy

Could targeting cGAS-STING represent a new treatment avenue for uveitis?

  • May 21, 2026

  • 3 min